18 and older, female only, with Recurrent Cervical Cancer or Stage IIIA Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Progression-free SurvivalPrimary· From the first day of treatment to the first observation of disease progression or death due to any cause, assessed at 6 months
Progression-free survival measures the length of time a patient with cancer does not experience disease progression or death. It is defined as the time from first day of treatment to the first observation of disease progression or death due to any cause. If a patient has not progressed or died, progression-free survival is censored at the time of last follow-up.
Group
Value
95% CI
Eribulin Mesylate
2.5
1.2 – 4.2
Number of Participants With Serious Adverse Events (SAEs)Primary· At study drug administration until 30 days following the last dose. Assessed up to 2 years.
Safety evaluation according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.3 was used to grade all SAEs. Grade 3+ hematologic and non-hematologic toxicities are reported.
Group
Value
95% CI
Eribulin Mesylate
25
Best Overall Response (BOR)Secondary· Every 6 weeks from start of treatment until occurrence of progressive disease, assessed up to 4 years.
BOR is defined as the best response recorded from the start of treatment until disease progression/recurrence, evaluated according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1 for target lesions and assessed by MRI: Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR) = at least a 30% decrease in the sum of the diameters of the target lesions compared to the baseline; Stable Disease = Neither enough shrinkage for PR nor enough growth for PD; Progressive Disease = at least a 20% increase in the sum of the diameters of the target lesions f
Group
Value
95% CI
Eribulin Mesylate
1
Eribulin Mesylate
5
Eribulin Mesylate
13
Eribulin Mesylate
11
Overall Survival (OS)Secondary· From first day of treatment to time of death due to any cause, assessed up to 2 years
Overall survival is defined as the time from first day of treatment to time of death due to any cause. If a patient is still alive, survival time is censored at the time of last follow-up.
Group
Value
95% CI
Eribulin Mesylate
6.5
4.5 – 12.7
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse events were collected from the time the subject received the initial study drug administration and continued until 30 days after the last dose or until resolution of adverse event if beyond 30 days after last dose. Assessed up to 2 years..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Eribulin Mesylate
Serious: 25/32 (78%)
Deaths: 0/32
Serious adverse events (41 terms)
Reaction
System
Eribulin Mesylate
Anemia
Blood and lymphatic system disorders
—
Neutrophil count decreased
Investigations
—
White blood cell decreased
Investigations
—
Abdominal Pain
Gastrointestinal disorders
—
Hematuria
Renal and urinary disorders
—
Hyperglycemia
Metabolism and nutrition disorders
—
Paresthesia
Nervous system disorders
—
Back pain
Musculoskeletal and connective tissue disorders
—
Fatigue
General disorders
—
Headache
Nervous system disorders
—
Hypotension
Vascular disorders
—
Pain in extremity
Musculoskeletal and connective tissue disorders
—
Rectal hemorrhage
Gastrointestinal disorders
—
Sepsis
Infections and infestations
—
Thromboembolic event
Vascular disorders
—
Urinary tract infection
Infections and infestations
—
Anorexia
Metabolism and nutrition disorders
—
Aspartate Aminotransferase increased
Investigations
—
Bone pain
Musculoskeletal and connective tissue disorders
—
Cystitis noninfective
Renal and urinary disorders
—
Dehydration
Metabolism and nutrition disorders
—
Diarrhea
Gastrointestinal disorders
—
Dysphagia
Gastrointestinal disorders
—
Dyspnea
Respiratory, thoracic and mediastinal disorders
—
Febrile Neutropenia
Blood and lymphatic system disorders
—
Other adverse events (106 terms — click to expand)
This phase II trial studies how well eribulin mesylate works in treating patients with advanced or recurrent cervical cancer. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT02120469 — Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
· Phase 1
· completed
NCT01613768 — Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
· Phase 2
· completed
NCT01328249 — Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Brea
· Phase 2
· completed
NCT01126736 — Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients
· Phase 1, PHASE2
· completed
Other recruiting trials for Recurrent Cervical Cancer
Currently open trials in the same condition.
NCT07472153 — PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemother
· Phase 2, PHASE3
· recruiting
Other University of Southern California trials
Trials by the same sponsor.
NCT07288463 — Hearing Loss and Genetic Risks for Alzheimer's Disease and Related Dementia
· NA
· not yet recruiting
NCT05914233 — Non-invasive Ultrasound Retinal Stimulation for Vision Restoration
· NA
· not yet recruiting
NCT06163664 — Role of ChatGPT in Vestibular Schwannoma Management
· NA
· withdrawn
NCT07332312 — A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Ind
· NA
· not yet recruiting
NCT07290478 — Encouraging Older Adults and Adults With Serious Illness to Designate a Health Care Proxy
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Southern California
Last refreshed: 6 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01676818.